此外，因认购事项的所有条件均已获达成，公司已于2026年2月2日按每股认购股份3.32港元配发及发行 4518.1万股认购股份(相等于根据配售事项成功配售的配售股份数目)予卖方。认购股份相当于经配发及 发行认购股份扩大后的公司已发行股本约3.26%。 自认购事项收取的所得款项净额约为1.443亿港元。公司拟将所得款项净额用作以下用途：约90%将用 于加速公司AI驱动的慢病管理平台的发展，包括模型发展及优化、基础设施及计算资源扩展、AI及医 疗专家领域的人才招来、数据采集标注及知识库开发，以及推出及推广AI增强服务以覆盖服务不足的 患者及医生群体;约10%将用于营运资金及其他一般企业用途。 方舟健客(06086)发布公告，配售事项完成已于2026年1月29日落实及认购事项完成已于2026年2月2日落 实。根据配售及认购协议条款及条件合共4518.1万股配售股份已由配售代理按每股股份3.32港元的配售 价成功配售予不少于6名承配人。 ...

智通财经APP讯，方舟健客(06086)发布公告，配售事项完成已于2026年1月29日落实及认购事项完成已 于2026年2月2日落实。根据配售及认购协议条款及条件合共4518.1万股配售股份已由配售代理按每股股 份3.32港元的配售价成功配售予不少于6名承配人。 自认购事项收取的所得款项净额约为1.443亿港元。公司拟将所得款项净额用作以下用途：约90%将用 于加速公司AI驱动的慢病管理平台的发展，包括模型发展及优化、基础设施及计算资源扩展、AI及医 疗专家领域的人才招来、数据采集标注及知识库开发，以及推出及推广AI增强服务以覆盖服务不足的 患者及医生群体;约10%将用于营运资金及其他一般企业用途。 此外，因认购事项的所有条件均已获达成，公司已于2026年2月2日按每股认购股份3.32港元配发及发行 4518.1万股认购股份(相等于根据配售事项成功配售的配售股份数目)予卖方。认购股份相当于经配发及 发行认购股份扩大后的公司已发行股本约3.26%。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 方舟云康控股有限公司 呈交日期： 2026年2月2日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06086 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不包括庫存股份）數 目 | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公 告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責任。 本公告並不構成在美國境內購買或認購證券的要約或招攬，亦不屬於任何有 關要約或招攬的一部分。本公告所述證券並未且將不會根據 1933 年美國證券 法（經修訂）（「美國證券法」）或美國任何其他州證券法律登記，亦不得在美 國境內提呈或出售，除非根據美國證券法進行登記或獲豁免或為毋須遵守美 國證券法登記規定之交易。本公司無意根據美國證券法登記本公告內所指之 任何證券，亦無意在美國進行證券之公開發售。本公告所述證券將不會於美 國境內或該等發售受到限制或禁止的任何其他司法權區進行公開發售。 Fangzhou Inc. 方舟云康控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6086） 完成配售現有股份及 根據一般授權 先舊後新認購新股份 整體協調人及獨家配售代理 茲提述方舟云康控股有限公司（「本公司」）日期為2026年1月2 7日的公告 （「該公告」），內容有關配售事項及認購事項。除本公告另有界定者外 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 方舟云康控股有限公司 呈交日期: 2026年2月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06086 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,500,000,000 | USD | | 0.00002 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 2,500,000,000 | USD | | 0.00002 | USD | | 50,000 | 本月底法定/註冊 ...

3、港股通5日占比增持榜（前10名） | 公司名称 | 占比值变动 | 最新持股比例 | | --- | --- | --- | | 钧达股份(02865) | +12.94% | 62.00% | | 南华期货股份(02691) | +9.45% | 11.03% | | 山东墨龙(00568) | +3.83% | 61.06% | | 君实生物(01877) | +3.41% | 56.39% | | 百奥赛图-B(02315) | +3.25% | 23.55% | | 中伟新材(02579) | +2.87% | 16.58% | | 长飞光纤光缆(06869) | +2.50% | 57.18% | | 南方东西精选(03441) | +2.33% | 16.05% | | 新意网集团(01686) | +2.26% | 7.24% | | 方舟健客(06086) | +1.96% | 6.24% | 智通财经APP获悉，根据2026年1月30日披露数据，山东墨龙（00568）、钧达股份（02865）、京城机 电股份（00187）港股通持股占比增加值最大，分别增加2.80%、2.32%、1.51% ...

Core Viewpoint - Ark Health has successfully raised HKD 150 million through a share placement at a price of HKD 3.32 per share, representing approximately 3.26% of the company's expanded issued share capital [1] Group 1: Fund Utilization - The company plans to allocate approximately 90% of the net proceeds, around HKD 129 million, to accelerate the development of its "AI + Chronic Disease Management" platform [1] - The funds will be used for model development and optimization, expansion of infrastructure and computing resources, recruitment of AI and clinical professionals, data collection and annotation, and knowledge base construction [1] - The company aims to launch AI-enhanced services to cover a broader range of patients and healthcare professionals [1]

Core Viewpoint - Fangzhou Inc. has issued a positive profit forecast for 2025, highlighting stronger-than-expected revenue growth and its first year of full profitability, validating the commercial viability of its "AI + chronic care services" model [1][2]. Financial Performance - The company expects full-year revenue for 2025 to reach between RMB 3.5 billion and RMB 3.55 billion, representing year-on-year growth of approximately 30% [2]. - Fangzhou forecasts a net profit of RMB 7 million to RMB 10 million, marking a transition to comprehensive profitability after achieving adjusted profitability in 2024 [2]. Business Model and Growth Drivers - Revenue increase is attributed to the expansion of chronic disease management services and the upgrading of its platform through AI technologies, attracting more physicians and patients [3]. - The earnings improvement reflects a qualitative shift in business fundamentals, validating the long-term sustainability of its chronic disease management model [4]. Strategic Developments - In 2025, Fangzhou completed a strategic upgrade to its "AI + H2H (Hospital-to-Home)" model, applying AI across the entire service chain [5]. - The company began benchmarking against OpenEvidence and accelerated large-model deployment, completing key technical positioning ahead of many peers [5]. Market Recognition - Citi Research initiated coverage on Fangzhou with a "Buy" rating and a target price of HK$8.50 [6]. - Gelonghui Research Institute projects the company's revenue to reach HK$3.5 billion in 2025 and HK$4.8 billion in 2026, indicating a period of value re-rating driven by scale expansion and improving profitability [6]. Future Outlook - Fangzhou plans to refine its AI + H2H full-cycle smart healthcare ecosystem and deepen technology research and service innovation [7]. - The company aims to leverage its platform capabilities to support China's "Healthy China 2030" initiative while setting benchmarks for high-quality development in the digital healthcare industry [7].

Core Viewpoint - Fangzhou Inc. has successfully completed a HK$150 million share placement to enhance its balance sheet and accelerate investments in AI and platform upgrades [1][2]. Group 1: Fundraising and Financials - The shares were priced at HK$3.32 each, representing approximately 3.26% of the Company's enlarged issued share capital post-subscription [2]. - Fangzhou plans to allocate around 90% of the net proceeds to develop its AI-driven chronic disease management platform, focusing on model development, infrastructure expansion, talent recruitment, data collection, and marketing of AI-enhanced services [3]. - The fundraising follows a positive profit alert, with projected 2025 revenue between RMB 3.5 billion and RMB 3.55 billion, indicating a year-on-year growth of approximately 30%, and a net profit of RMB 7 million to RMB 10 million, marking the first full year of profit for the Company [6]. Group 2: Industry Context and Strategic Direction - The fundraising occurs amid a resurgence in medical AI, as both global and domestic technology players are advancing healthcare-focused large language models (LLMs) [4]. - Fangzhou has completed a significant upgrade of its "AI + H2H (Hospital-to-Home)" ecosystem, integrating AI throughout the chronic disease management value chain to enhance patient care and medical resource efficiency [4]. - The Company is positioned as a leader in AI-enabled chronic care, attracting attention from institutional investors as China's healthcare sector explores innovative models [5]. - Looking forward, Fangzhou aims to leverage technology and AI to improve chronic disease management and support China's "Healthy China 2030" initiative [7]. Group 3: Company Overview - Fangzhou Inc. is recognized as China's leading online chronic disease management platform, with 52.8 million registered users and 229,000 physicians as of June 30, 2025 [8]. - The Company specializes in providing tailored medical care and AI-enabled precision medicine solutions [8].

智通财经1月27日讯（编辑 胡家荣）今日港股互联网医疗股延续跌势。截至发稿，方舟健客(06086.HK)跌18.75%、麦迪卫康(02159.HK)跌3.79%、平安好医 生(01833.HK)跌1.64%。 | 代码 | 名称 | 最新价 | 涨跌额 | 涨跌幅 ◆ | | --- | --- | --- | --- | --- | | 06086 | 方舟健客 | 3.070 | -0.700 | -18.57% | | 02159 | 麦迪卫康 | 1.270 | -0.050 | -3.79% | | 01833 | 平安好医生 | 14.970 | -0.250 | -1.64% | | 00241 | 阿里健康 | 6.690 | -0.040 | -0.59% | | 06618 | 京东健康 | 64.350 | -0.050 | -0.08% | 从上图来看，方舟健客跌幅居前。根据当日公告，该公司拟以"先旧后新"方式实施股份配售。 具体来看，方舟健客计划配售4,518.1万股，占经扩大后已发行股本约3.26%；配售价为每股3.32港元，较前一交易日收市价折让约11.94%。本次配售预计募 集 ...